Advertisement

Medical Oncology

, 36:98 | Cite as

Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up

  • Yanling Wang
  • Qijun Li
  • Jing Wang
  • Mengting Tong
  • Haibo Xing
  • Yanan Xue
  • Hongming Pan
  • Changxing Huang
  • Da LiEmail author
Review Article
  • 54 Downloads

Abstract

Small cell carcinoma of the bladder (SCCB) is a rare disease associated with high invasiveness and mortality. Histologically, SCCB is difficult to distinguish from small cell lung cancer (SCLC); however, it shares more similar molecular alterations with urothelial carcinoma (UC). As a result, now, the widely accepted theory about the cells of origin is that SCCB and UC probably have a common clone origin. Even the former probably comes from a preexisting UC. At present, given its rarity, early diagnoses, treatments, and follow-ups are not well established, which are vital to patients with SCCB. Inspirationally, in recent years, with the development of molecular diagnostic methods, molecular alterations of SCCB have been understood partially, which are propitious to excavate new potential therapeutic strategies and establish sound follow-ups. Therefore, the future will be light for patients with SCCB.

Keywords

Small cell carcinoma of the bladder Urothelial carcinoma Small cell lung cancer Molecular alterations Treatment Follow-up 

Notes

Funding

The National Natural Science Foundation of China (No. 81573003) and Zhejiang Province Natural Science Foundation and Zhejiang Society of Mathematical Medicine Joint Foundation (No. LSY19H160005).

Compliance with ethical standards

Conflict of interests

The authors have declared that no competing interest exists.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.  https://doi.org/10.3322/caac.21442.CrossRefPubMedGoogle Scholar
  2. 2.
    Niu Q, Lu Y, Xu S, Shi Q, Guo B, Guo Z, et al. Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study. Cancer Manag Res. 2018;10:4479–89.  https://doi.org/10.2147/CMAR.S175286.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106–19.  https://doi.org/10.1016/j.eururo.2016.02.028.CrossRefPubMedGoogle Scholar
  4. 4.
    Erdem GU, Ozdemir NY, Demirci NS, Sahin S, Bozkaya Y, Zengin N. Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Res Opin. 2016;32(6):1013–21.  https://doi.org/10.1185/03007995.2016.1155982.CrossRefPubMedGoogle Scholar
  5. 5.
    Schreiber D, Rineer J, Weiss J, Leaf A, Karanikolas N, Rotman M, et al. Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. Am J Clin Oncol Cancer. 2013;36(2):126–31.  https://doi.org/10.1097/COC.0b013e3182438c71.CrossRefGoogle Scholar
  6. 6.
    Chang MT, Penson A, Desai NB, Socci ND, Shen R, Seshan VE, et al. Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin Cancer Res. 2018;24(8):1965–73.  https://doi.org/10.1158/1078-0432.CCR-17-2655.CrossRefPubMedGoogle Scholar
  7. 7.
    Shen PY, Jing Y, Zhang RY, Cai MC, Ma P, Chen H, et al. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. Oncogene. 2018;37(22):3039–44.  https://doi.org/10.1038/s41388-018-0192-5.CrossRefPubMedGoogle Scholar
  8. 8.
    Oser MG, Janne PA. Small-cell neuroendocrine tumors: cell state trumps the oncogenic driver. Clin Cancer Res. 2018;24(8):1775–6.  https://doi.org/10.1158/1078-0432.CCR-17-3646.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540.e25–556.e25.  https://doi.org/10.1016/j.cell.2017.09.007.CrossRefGoogle Scholar
  10. 10.
    Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104–10.  https://doi.org/10.1038/ng.2396.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, et al. Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D/MLL2: CALGB 151111 (alliance). J Thorac Oncol. 2017;12(4):704–13.  https://doi.org/10.1016/j.jtho.2016.12.011.CrossRefPubMedGoogle Scholar
  12. 12.
    Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36(28):3943–56.  https://doi.org/10.1038/onc.2016.502.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–86.  https://doi.org/10.1101/gad.190678.112.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495–501.  https://doi.org/10.1038/nature12912.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Berman-Booty LD, Knudsen KE. Models of neuroendocrine prostate cancer. Endocr Relat Cancer. 2015;22(1):R33–49.  https://doi.org/10.1530/ERC-14-0393.CrossRefPubMedGoogle Scholar
  16. 16.
    Di Agostino S, Fontemaggi G, Strano S, Blandino G, D’Orazi G. Targeting mutant p53 in cancer: the latest insights. J Exp Clin Cancer Res. 2019;38(1):290.  https://doi.org/10.1186/s13046-019-1302-0.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26(2):199–212.  https://doi.org/10.1038/s41418-018-0246-9.CrossRefPubMedGoogle Scholar
  18. 18.
    Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ. 2018;25(1):161–8.  https://doi.org/10.1038/cdd.2017.185.CrossRefPubMedGoogle Scholar
  19. 19.
    Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, Zhang R. Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem. 2014;21(5):553–74.  https://doi.org/10.2174/09298673113206660325.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, et al. Systemic treatments in MDM2 positive intimal sarcoma: a multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2019.  https://doi.org/10.1002/cncr.32508.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang Q, Zeng SX, Lu H. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014;85:281–319.  https://doi.org/10.1007/978-94-017-9211-0_16.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Yang L, Song T, Cheng Q, Chen L, Chen J. Mutant p53 sequestration of the MDM2 acidic domain inhibits E3 ligase activity. Mol Cell Biol. 2019.  https://doi.org/10.1128/mcb.00375-18.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Dyson NJ. RB1: a prototype tumor suppressor and an enigma. Genes Dev. 2016;30(13):1492–502.  https://doi.org/10.1101/gad.282145.116.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    D’Arcangelo D, Tinaburri L, Dellambra E. The role of p16(INK4a) pathway in human epidermal stem cell self-renewal, aging and cancer. Int J Mol Sci. 2017.  https://doi.org/10.3390/ijms18071591.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Fu HC, Chuang IC, Yang YC, Chuang PC, Lin H, Ou YC, et al. Low P16(INK4A) expression associated with high expression of cancer stem cell markers predicts poor prognosis in cervical cancer after radiotherapy. Int J Mol Sci. 2018.  https://doi.org/10.3390/ijms19092541.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    He SH, Sharpless NE. Senescence in health and disease. Cell. 2017;169(6):1000–11.  https://doi.org/10.1016/j.cell.2017.05.015.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Noe M, Hackeng WM, de Leng WWJ, Vergeer M, Vleggaar FP, Morsink FHM, et al. Well-differentiated pancreatic neuroendocrine tumor in a patient with familial atypical multiple mole melanoma syndrome (FAMMM). Am J Surg Pathol. 2019.  https://doi.org/10.1097/PAS.0000000000001314.CrossRefPubMedGoogle Scholar
  28. 28.
    George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53.  https://doi.org/10.1038/nature14664.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Meder L, Konig K, Ozretic L, Schultheis AM, Ueckeroth F, Ade CP, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer. 2016;138(4):927–38.  https://doi.org/10.1002/ijc.29835.CrossRefPubMedGoogle Scholar
  30. 30.
    Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N, et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov. 2014;4(9):1014–21.  https://doi.org/10.1158/2159-8290.CD-14-0380.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Rickman DS, Beltran H, Demichelis F, Rubin MA. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med. 2017;23(6):1–10.  https://doi.org/10.1038/nm.4341.CrossRefPubMedGoogle Scholar
  32. 32.
    Cheng L, Jones TD, McCarthy RP, Eble JN, Wang MS, MacLennan GT, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005;166(5):1533–9.  https://doi.org/10.1016/S0002-9440(10)62369-3.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Pan CX, Zhang H, Lara PN Jr, Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther. 2006;6(12):1707–13.  https://doi.org/10.1586/14737140.6.12.1707.CrossRefPubMedGoogle Scholar
  34. 34.
    Abat D, Demirhan O, Inandiklioglu N, Tunc E, Erdogan S, Tastemir D, et al. Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer. Oncol Lett. 2014;8(1):25–32.  https://doi.org/10.3892/ol.2014.2108.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Worst TS, Weis CA, Stohr R, Bertz S, Eckstein M, Otto W, et al. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Sci Rep. 2018.  https://doi.org/10.1038/s41598-018-32569-x.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kouba EJ, Cheng L. Understanding the genetic landscape of small cell carcinoma of the urinary bladder and implications for diagnosis, prognosis, and treatment: a review. JAMA Oncol. 2017;3(11):1570–8.  https://doi.org/10.1001/jamaoncol.2016.7013.CrossRefPubMedGoogle Scholar
  37. 37.
    Gupta A, Shah K, Oza MJ, Behl T. Reactivation of p53 gene by MDM2 inhibitors: a novel therapy for cancer treatment. Biomed Pharmacother. 2019;109:484–92.  https://doi.org/10.1016/j.biopha.2018.10.155.CrossRefPubMedGoogle Scholar
  38. 38.
    Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). Oncotargets Ther. 2019;12:2903–10.  https://doi.org/10.2147/Ott.S172315.CrossRefGoogle Scholar
  39. 39.
    Oliner JD, Saiki AY, Caenepeel S. The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harb Perspect Med. 2016.  https://doi.org/10.1101/cshperspect.a026336.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, et al. Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097. Mol Cancer Ther. 2015;14(10):2249–59.  https://doi.org/10.1158/1535-7163.Mct-15-0429.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Giedl J, Rogler A, Wild A, Riener MO, Filbeck T, Burger M, et al. TERT core promotor mutations in early-onset bladder cancer. J Cancer. 2016;7(8):915–20.  https://doi.org/10.7150/jca.15006.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Avogbe PH, Manel A, Vian E, Durand G, Forey N, Voegele C, et al. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. EBioMedicine. 2019;44:431–8.  https://doi.org/10.1016/j.ebiom.2019.05.004.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Zheng XY, Jian ZG, Bezerra SM, Faraj SF, Munari E, Fallon JT, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol. 2014.  https://doi.org/10.1186/s13045-014-0047-7.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Rane JK, Simms MS, Maitland NJ. Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360-6: telomerase expression and stem cells: urologic epithelial perspective. Eur Urol. 2014;65(6):E85–6.  https://doi.org/10.1016/j.eururo.2014.02.030.CrossRefPubMedGoogle Scholar
  45. 45.
    Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Can Res. 2013;73(24):7162–7.  https://doi.org/10.1158/0008-5472.Can-13-2498.CrossRefGoogle Scholar
  46. 46.
    Fujii T, Shimada K, Tatsumi Y, Hatakeyama K, Obayashi C, Fujimoto K, et al. microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. BMC Cancer. 2015;15:818.  https://doi.org/10.1186/s12885-015-1846-0.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Van Batavia J, Yamany T, Molotkov A, Dan H, Mansukhani M, Batourina E, et al. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol. 2014;16(10):982–91.  https://doi.org/10.1038/ncb3038.CrossRefPubMedGoogle Scholar
  48. 48.
    Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer: what limits limited disease? Lung Cancer. 2002;37(3):271–6.CrossRefGoogle Scholar
  49. 49.
    Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(3):300–11.  https://doi.org/10.1016/j.jtho.2015.10.008.CrossRefPubMedGoogle Scholar
  50. 50.
    Bryant CM, Dang LH, Stechmiller BK, Gilbert SM, Morris CG, Zlotecki RA. Treatment of small cell carcinoma of the bladder with chemotherapy and radiation after transurethral resection of a bladder tumor. Am J Clin Oncol. 2016;39(1):69–75.  https://doi.org/10.1097/COC.0000000000000027.CrossRefPubMedGoogle Scholar
  51. 51.
    Montie JE. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 64 patients. J Urol. 2005;173(6):1920–1.  https://doi.org/10.1097/01.ju.0000161245.95285.b2.CrossRefPubMedGoogle Scholar
  52. 52.
    Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M.D. Anderson cancer experience. J Urol. 2004;172(2):481–4.CrossRefGoogle Scholar
  53. 53.
    Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol. 2005;174(1):93–6.  https://doi.org/10.1097/01.ju.0000162085.20043.1f.CrossRefPubMedGoogle Scholar
  54. 54.
    Walther PJ. Adjuvant/neo-adjuvant etoposide/cisplatin and cystectomy for management of invasive small cell carcinoma of the bladder. J Urol. 2002;167(4):285.Google Scholar
  55. 55.
    Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, et al. Small cell carcinoma of the urinary bladder: a retrospective, multicenter rare cancer network study of 107 patients. Int J Radiat Oncol Biol Phys. 2015;92(4):904–10.  https://doi.org/10.1016/j.ijrobp.2015.03.019.CrossRefPubMedGoogle Scholar
  56. 56.
    Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009;27(16):2592–7.  https://doi.org/10.1200/Jco.2008.19.0256.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013;64(2):307–13.  https://doi.org/10.1016/j.eururo.2012.04.020.CrossRefPubMedGoogle Scholar
  58. 58.
    Bhatt VR, Loberiza FR Jr, Tandra P, Krishnamurthy J, Shrestha R, Wang J. Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. Rare Tumors. 2014;6(1):5043.  https://doi.org/10.4081/rt.2014.5043.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Kaushik D, Frank I, Boorjian SA, Cheville JC, Eisenberg MS, Thapa P, et al. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol. 2015;22(6):549–54.  https://doi.org/10.1111/iju.12729.CrossRefPubMedGoogle Scholar
  60. 60.
    Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer. 1999;86(11):2346–52.CrossRefGoogle Scholar
  61. 61.
    Meijer RP, Meinhardt W, van der Poel HG, van Rhijn BW, Kerst JM, Pos FJ, et al. Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. Int J Urol. 2013;20(8):778–84.  https://doi.org/10.1111/iju.12038.CrossRefPubMedGoogle Scholar
  62. 62.
    Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, van Boven H, Meinhardt W, et al. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology. 2005;65(2):295–9.  https://doi.org/10.1016/j.urology.2004.09.049.CrossRefPubMedGoogle Scholar
  63. 63.
    Bex A, de Vries R, Pos F, Kerst M, Horenblas S. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol. 2009;27(1):101–6.  https://doi.org/10.1007/s00345-008-0304-x.CrossRefPubMedGoogle Scholar
  64. 64.
    Mattes MD, Kan CC, Dalbagni G, Zelefsky MJ, Kollmeier MA. External beam radiation therapy for small cell carcinoma of the urinary bladder. Pract Radiat Oncol. 2015;5(1):e17–22.  https://doi.org/10.1016/j.prro.2014.03.013.CrossRefPubMedGoogle Scholar
  65. 65.
    Akamatsu H, Nakamura K, Ebara T, Inaba K, Itasaka S, Jingu K, et al. Organ-preserving approach via radiotherapy for small cell carcinoma of the bladder: an analysis based on the Japanese Radiation Oncology Study Group (JROSG) survey. J Radiat Res. 2019.  https://doi.org/10.1093/jrr/rrz018.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Germino E, Fischer-Valuck BW, Rudra S, Rao YJ, Contreras J, Abraham C, et al. Radiation therapy as definitive local treatment in patients with limited-stage small cell carcinoma of the bladder: does total dose matter? Bladder Cancer. 2018;4(3):311–7.  https://doi.org/10.3233/BLC-180165.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    van de Kamp M, Meijer R, Pos F, Kerst M, van Werkhoven E, van Rhijn B, et al. Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: characteristics, treatment, and outcome. Urol Oncol. 2018;36(6):307.e1–8.  https://doi.org/10.1016/j.urolonc.2018.02.015.CrossRefGoogle Scholar
  68. 68.
    Hsu FS, Su CH, Huang KH. A comprehensive review of US FDA-approved immune checkpoint inhibitors in urothelial carcinoma. J Immunol Res. 2017;2017:6940546.  https://doi.org/10.1155/2017/6940546.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Schultheis AM, Scheel AH, Ozretic L, George J, Thomas RK, Hagemann T, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015;51(3):421–6.  https://doi.org/10.1016/j.ejca.2014.12.006.CrossRefPubMedGoogle Scholar
  70. 70.
    Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, et al. Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target. Clin Cancer Res. 2019;25(1):210–21.  https://doi.org/10.1158/1078-0432.Ccr-18-1278.CrossRefPubMedGoogle Scholar
  71. 71.
    Mandelkow T, Blessin NC, Lueerss E, Pott L, Simon R, Li WC, et al. Immune exclusion is frequent in small-cell carcinoma of the bladder. Dis Markers. 2019.  https://doi.org/10.1155/2019/2532518.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30.  https://doi.org/10.1038/nature21349.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical Oncology, Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhouChina
  2. 2.Second Department of Medical OncologyThe Fourth Affiliated Hospital of Xinjiang Medical UniversityUrumqiChina
  3. 3.Deparment of ICU, Xiasha Campus, Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhouChina
  4. 4.Department of Medical OncologyAffiliated Hospital of Hangzhou Normal UniversityHangzhouChina

Personalised recommendations